Phibro Animal Health (NASDAQ:PAHC) Stock Price Up 6.8% on Analyst Upgrade

Phibro Animal Health Co. (NASDAQ:PAHC)’s share price was up 6.8% on Monday after Barclays raised their price target on the stock from $20.00 to $22.00. Barclays currently has an underweight rating on the stock. Phibro Animal Health traded as high as $24.21 and last traded at $25.30. Approximately 92,480 shares were traded during mid-day trading, a decline of 40% from the average daily volume of 154,656 shares. The stock had previously closed at $23.69.

PAHC has been the subject of a number of other research reports. StockNews.com lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Morgan Stanley lifted their price objective on Phibro Animal Health from $20.00 to $25.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average price target of $21.00.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently modified their holdings of PAHC. Geode Capital Management LLC lifted its position in shares of Phibro Animal Health by 5.7% in the third quarter. Geode Capital Management LLC now owns 507,469 shares of the company’s stock valued at $11,430,000 after acquiring an additional 27,201 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Phibro Animal Health by 8.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 290,656 shares of the company’s stock valued at $6,104,000 after buying an additional 22,263 shares during the period. Bank of New York Mellon Corp raised its position in shares of Phibro Animal Health by 2.9% during the 4th quarter. Bank of New York Mellon Corp now owns 272,632 shares of the company’s stock valued at $5,725,000 after buying an additional 7,747 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Phibro Animal Health by 116.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company’s stock valued at $4,330,000 after buying an additional 103,491 shares during the period. Finally, Segall Bryant & Hamill LLC raised its position in Phibro Animal Health by 1.7% in the third quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock valued at $3,931,000 after purchasing an additional 2,971 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Trading Up 7.7 %

The company has a market cap of $1.03 billion, a PE ratio of 53.27, a price-to-earnings-growth ratio of 0.53 and a beta of 0.52. The company has a quick ratio of 1.69, a current ratio of 3.20 and a debt-to-equity ratio of 2.99. The business has a 50-day simple moving average of $21.90 and a 200-day simple moving average of $21.70.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. On average, analysts predict that Phibro Animal Health Co. will post 1.94 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Wednesday, March 5th will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date is Wednesday, March 5th. Phibro Animal Health’s dividend payout ratio is currently 100.00%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.